Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $25.5252W HIGH $43.49
Volume
128.11 K
Value Traded
22.04 M
Short % Float
9.22%
+1.21%Week
-3.6%1 Month
+8.9%3 Month
+38.87%6 Month
-7.97%5 Year
-24.61%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
2.35 B
EPS (TTM)
3.11
P/E Ratio
12.89
Ent. Value
1.86 B
Total Shares
58.25 M
Float Shares
50.20 M
Insiders
13.80%
Institutions
95.55%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
HRMY Catalyst Timeline
Dated clinical, regulatory and corporate events for Harmony Biosciences Holdings, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Harmony Biosciences Holdings, Inc.
197Total events
26Upcoming
60Tier-1 (high impact)
2019 to 2028Coverage
Upcoming catalysts 2
Event history 50
◆Poster PresentationHBS-301Presentation
Poster presentation of Phase 3 ONSTRIDE-1 and ONSTRIDE-2 trials of HBS-301 at 17th European Narcolepsy Days
narcolepsy and idiopathic hypersomniasource ↗
◆Poster PresentationEPX-100Presentation
Poster presentation of preliminary results from open-label extension phase of ARGUS study
Dravet syndromesource ↗
▲Patent GrantedPitolisantApprovedIP / Competition
Exclusive license to Novitium's issued amorphous pitolisant patent
▲Quarterly UpdateWAKIXApprovedCorporate
Preliminary Q2 2026 net product revenue of ~$261M for WAKIX
◆Trial InitiationBP-205Trial
Initiating Phase 1b study in sleep-deprived healthy volunteers in Q3 2026
sleep-deprived healthy volunteerssource ↗
▲FDA Filing AcceptedPitolisantApprovedRegulatory Filing
Pitolisant GR NDA accepted by FDA in July 2026
narcolepsysource ↗
▲Quarterly UpdateWAKIXApprovedCorporate
Q2 2026 net revenue of $261.3 million for WAKIX
narcolepsysource ↗
◆Poster PresentationEPX-100Presentation
Poster presentation of open-label extension data from Phase 3 ARGUS trial at AAN 2026
Dravet syndromesource ↗
◆Oral PresentationPresentation
Open-label extension data from Phase 3 ARGUS trial at 2026 AAN Annual Meeting
◆Oral PresentationPresentation
Harmony Biosciences to participate in fireside chat at 25th Annual Needham Virtual Healthcare Conference
◆Topline ReadoutBP1.15205Clinical Data
Orexin-2 agonist BP1.15205 Phase 1 clinical data expected in mid-2026
▲Supplemental ApprovalWAKIXApprovedFDA Decision
FDA approval of sNDA for WAKIX for cataplexy in pediatric narcolepsy patients 6 years and older
cataplexy in pediatric narcolepsysource ↗
●Oral PresentationPresentation
Management presentation at 44th Annual J.P. Morgan Healthcare Conference
▲Quarterly UpdateWAKIXApprovedCorporate
WAKIX 2025 preliminary net revenue of ~$868 million
narcolepsysource ↗
◆FDA ApprovalPitolisantApprovedFDA Decision
Potential FDA approval of pitolisant sNDA for idiopathic hypersomnia
Idiopathic Hypersomniasource ↗
▲Trial InitiationPitolisantApprovedTrial
Initiation of pitolisant-HD pivotal Phase 3 trial in narcolepsy
Narcolepsysource ↗
◆Poster PresentationEPX-100Presentation
Poster presentation of open-label extension data from Phase 3 ARGUS trial at AES 2025
Dravet syndromesource ↗
●IND SubmissionPitolisantApprovedIND
Pitolisant HD IND submitted
narcolepsy and idiopathic hypersomniasource ↗
▲Quarterly UpdateCorporate
Preliminary Q3 2025 WAKIX performance and raised 2025 revenue guidance
◆Trial InitiationPitolisantApprovedTrial
Phase 3 trials for pitolisant HD expected to initiate in Q4 2025
narcolepsy and idiopathic hypersomniasource ↗
◆Trial InitiationPitolisantApprovedTrial
Initiation of next-generation Pitolisant-HD Phase 3 registrational trials in Narcolepsy & IH
Narcolepsy & Idiopathic Hypersomniasource ↗
◆Topline ReadoutZYN002FiledClinical Data
Pivotal Phase 3 topline data for ZYN002 in fragile X syndrome
Fragile X Syndromesource ↗
▼Topline ReadoutZYN002FiledClinical Data
Topline results from Phase 3 RECONNECT Study of ZYN002 in Fragile X syndrome
Fragile X syndromesource ↗
▼Primary Endpoint MissedZYN002FiledClinical Data
Primary endpoint not met in RECONNECT Study
Fragile X syndromesource ↗
▲IP Litigation RulingWAKIXApprovedIP / Competition
Third settlement in ANDA litigation for WAKIX
narcolepsysource ↗
◆Topline ReadoutZYN002FiledClinical Data
Topline data readout from Phase 3 registrational trial with ZYN002 in Fragile X syndrome expected in Q3 2025
Fragile X syndromesource ↗
◆Oral PresentationBP1.15205Presentation
Orexin/BP1.15205 data presentation at SLEEP 2025 conference
Orexin-relatedsource ↗
◆Poster PresentationBP1.15205Presentation
Poster presentation of preclinical data for BP1.15205 at SLEEP 2025
narcolepsysource ↗
◆Oral PresentationBP1.15205Presentation
BP1.15205 data to be presented at SLEEP 2025 Conference
●IND SubmissionBP1.15205IND
IND submission for orexin-2 agonist on track for mid-2025
central disorders of hypersomnolencesource ↗
◆Topline ReadoutZYN002FiledClinical Data
Topline data from ZYN-002 Phase 3 RECONNECT trial on track for mid-2025
Fragile X syndromesource ↗
▲Enrollment CompleteZYN002FiledTrial
Completed recruitment of Phase 3 registrational trial of ZYN002 in Fragile X Syndrome
Fragile X Syndromesource ↗
Past FDA Catalysts and PDUFA Decisions
How HRMY actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-10-02 | HBS-301 | Phase 3 data presentation | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C52 / 100
Pipeline Score
$1.1B
Pipeline Value
$4.2B
Commercial Value
Undervalued
Valuation Signal
6
Drugs Scored
1.6x
rNPV / MCap
Top 15%
Small Cap(rank 100 of 658)
Percentile Rank
Harmony Biosciences Holdings, Inc. carries a moderate pipeline score (52/100), with $1.7B risk-adjusted pipeline value, led by Clemizole in Lennox Gastaut Syndrome (Phase 3).
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q)) Revenue $959.9M x 4.4 = $4.2B
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| WAKIX | $960M | - | - |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Clemizole Small moleculeNCT05066217 | Lennox Gastaut Syndrome | Phase 3 | RECRUITING | 260 | Nov 1, 2029 |
Clinical Trial Results
Readouts, endpoints and source filings for every HRMY program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| ZYN002 | Fragile X syndrome | Phase 3 | 2025-09-24 | The RECONNECT Study did not meet the primary endpoint due to a higher than expected placebo response rate.Read More | HARMONY BIOSCIENCES PROVIDES UPDATE FROM ITS PHASE 3 RECONNECT STUDY OF ZYN002 IN FRAGILE XRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Budur KumarOfficer (CHIEF MEDICAL OFFICER) | Option | 10,406 23,521 held | $30.69 | 09/18/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in HRMY
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Sofinnova Investments, Inc. | 0.2 % | 4.28 M | 152.69 K |
HRMY Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How HRMY ranks across every disease it competes in
Competitive Position is a premium feature
See how HRMY ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialHRMY News
HRMYHarmony Biosciences Announces Poster Presentation at the 17th European Narcolepsy Days
Harmony Biosciences has announced a poster presentation at the 17th European Narcolepsy Days, showcasing data from its ongoing Phase 3 trials of HBS-301. The trials include ONSTRIDE-1 for narcolepsy and ONSTRIDE-2 for idiopathic hypersomnia. HBS-301 is an investigational formulation aimed at treating excessive daytime sleepiness in these conditions.
Read more →HRMYHarmony Biosciences Recognizes World Narcolepsy Day 2026, Reflecting on Nearly a Decade of Commitment to the Sleep Community
Harmony Biosciences celebrated World Narcolepsy Day 2026, reflecting on its nearly ten-year commitment to the narcolepsy and sleep-wake community. The company has collaborated with patients, caregivers, and advocacy organizations to enhance care and understanding of sleep disorders. Their Patients at the Heart program has expanded to support various initiatives addressing the needs of those affected by sleep disorders.
Read more →HRMYHarmony Biosciences Announces Poster Presentations at the 16th European Epilepsy Congress
Harmony Biosciences announced its participation in the 16th European Epilepsy Congress, where it will present encore data on EPX-100, a treatment for Dravet syndrome and Lennox-Gastaut syndrome. The ongoing ARGUS and LIGHTHOUSE trials are currently enrolling participants. EPX-100 targets serotonin signaling and is developed using a unique zebrafish screening platform.
Read more →HRMYHarmony Biosciences to Participate in 2026 Cantor Global Healthcare Conference
Harmony Biosciences Holdings, Inc. will participate in the 2026 Cantor Global Healthcare Conference. The management team is scheduled for a fireside chat on September 10, 2026, at 10:20 a.m. E.T. A webcast of the chat will be available on the company's investor page. Harmony focuses on innovative therapies for rare neurological diseases.
Read more →HRMYHarmony Biosciences to Participate in Piper Sandler Virtual CNS Symposium
Harmony Biosciences Holdings, Inc. will participate in a fireside chat at the Piper Sandler Virtual CNS Symposium on August 13, 2026. The event will be accessible via a webcast on their investor page. This participation underscores the company's dedication to developing therapies for rare neurological diseases.
Read more →HRMY▲ +8.9%on this newsshared move
Harmony Biosciences Announces Record Q2 2026 Revenue and Shares Initial Clinical Data for Its Orexin-2 Agonist BP-205 Reinforcing Potential Best-in-Class Profile
Harmony Biosciences reported a record net revenue of $261.3 million for Q2 2026, reflecting a 30% year-over-year growth. The company also shared promising Phase 1 SAD data for its orexin-2 agonist BP-205, indicating a favorable safety profile. Plans for further clinical trials of BP-205 are set for mid-2027, aiming to explore multiple CNS indications. Despite strong revenue growth, the company faces challenges with rising costs and ongoing patent litigation.
Read more →HRMY▲ +10%on this news
Harmony Biosciences To Report Second Quarter 2026 Financial Results On August 4, 2026
Harmony Biosciences Holdings, Inc. will report its second quarter 2026 financial results on August 4, 2026, before U.S. markets open. A conference call and webcast will follow at 8:30 a.m. ET to discuss these results. Interested participants can join via a dedicated phone line or through the company's investor website.
Read more →HRMYHarmony Biosciences Preannounces Record Quarterly Revenue for Q2 2026, Reaffirms Full-Year 2026 Revenue Guidance, and Announces CFO Transition
Harmony Biosciences reported a record net product revenue of approximately $261 million for Q2 2026, reflecting a 30% increase year-over-year and a 21% increase from Q1. The company reaffirmed its full-year revenue guidance, indicating strong demand for its product WAKIX. Additionally, a transition in the CFO position was announced.
Read more →HRMYHarmony Biosciences Announces Poster Presentations at 2026 SLEEP Annual Meeting
Harmony Biosciences has announced poster presentations at the upcoming 2026 SLEEP Annual Meeting. The details regarding the specific presentations or topics have not been disclosed in the article. This event is expected to showcase advancements in sleep medicine and related research.
Read more →HRMYHarmony Biosciences to Participate in Upcoming Investor Conferences
Harmony Biosciences Holdings, Inc. announced its participation in two upcoming investor conferences: the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026, and the Oppenheimer CNS & Neuro-Muscular Summit on June 10, 2026. Both events will feature fireside chats with the management team and will take place in Miami, FL. Webcasts of these discussions will be available on the company's investor webpage.
Read more →HRMYHarmony Biosciences Reports Q1 Financial Results and Confirms 2026 Net Revenue Guidance of Over $1 Billion; Reinforces 2026 Strategic Priorities
Harmony Biosciences reported a Q1 2026 revenue of $215.4 million, marking a 17% year-over-year growth driven by strong demand for WAKIX®. Despite facing market access challenges, the company has reaffirmed its guidance for over $1 billion in net revenue for 2026. This follows a record performance over the last three quarters.
Read more →HRMYHarmony Biosciences to Report First Quarter 2026 Financial Results on May 7, 2026
Harmony Biosciences Holdings, Inc. will report its first quarter 2026 financial results on May 7, 2026. The company will host a conference call and webcast at 8:30 a.m. ET to discuss these results. Interested participants can join the call using the provided dial-in numbers and passcode.
Read more →HRMYHarmony Biosciences to Present Open-Label Extension Data From Phase 3 ARGUS Trial at the 2026 American Academy of Neurology Annual Meeting
Harmony Biosciences announced the presentation of open-label extension data from the Phase 3 ARGUS trial for EPX-100, targeting Dravet syndrome, at the 2026 American Academy of Neurology Annual Meeting. The trial is currently enrolling participants, and details about the trial can be found online. EPX-100 is an oral treatment aimed at modulating serotonin signaling in patients with Dravet syndrome.
Read more →HRMYHarmony Biosciences Appoints Glenn Reicin as Chief Financial Officer
Harmony Biosciences has appointed Glenn Reicin as Chief Financial Officer, effective immediately. His extensive experience in the biopharmaceutical sector is expected to support the company's strategic growth and financial strength. Harmony also reaffirmed its revenue guidance of $1.0 to $1.04 billion by 2026, indicating confidence in its future performance.
Read more →HRMYHarmony Biosciences Strengthens Executive Team With New Appointment and Announces Additions to Its Board
Harmony Biosciences has announced the strengthening of its executive team through new appointments. This move is expected to enhance the company's leadership structure and strategic direction. Additionally, the company has made additions to its board, signaling a commitment to growth and innovation.
Read more →HRMYHarmony Biosciences to Participate in 25th Annual Needham Virtual Healthcare Conference
Harmony Biosciences will participate in the 25th Annual Needham Virtual Healthcare Conference on April 13, 2026. The management team will engage in a fireside chat, which will be accessible via a webcast. This event highlights the company's commitment to developing therapies for rare neurological diseases.
Read more →HRMYHarmony Biosciences Reports Strong 2025 Financial Results and Reiterates 2026 Net Revenue Guidance of Over $1 Billion
Harmony Biosciences reported a strong financial performance for 2025, with Q4 revenue reaching $243.8 million, marking a 21% increase year-over-year. The company anticipates WAKIX will exceed $1 billion in revenue in 2026, supported by a robust pipeline of late-stage clinical trials. Harmony's continued growth reflects its strong market position in treating narcolepsy and expanding into additional indications.
Read more →About Harmony Biosciences Holdings, Inc.
Headquarters630 W GERMANTOWN PIKE, PLYMOUTH MEETING, PA, 19462
BIOPHARMAWATCH ELITE PLUS
Trade the next HRMY catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime